Stocks Health care INBP
OTC · Health careIntegrated Biopharma Inc (INBP)
Integrated Biopharma Inc reported revenue of $43.9M in fiscal 2026, down 19.3% from a year earlier. It posted a net loss of $2.8M. Operating cash flow minus capital spending left $895K of free cash flow in fiscal 2026. At June 30, 2026 it held $4.5M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 25, 2026.
Watch INBP in 60 secondsWhat Integrated Biopharma Inc does
Integrated Biopharma Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker INBP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $43.9M | -$2.8M | -$0.09 | $895K |
| 2025 | $54.4M | $808K | $0.03 | $1.9M |
| 2024 | $50.3M | $112K | $0.00 | $390K |
| 2023 | $50.7M | -$34K | $0.00 | $1.1M |
| 2022 | $56.2M | $3.8M | $0.12 | $3.6M |
| 2021 | $63.6M | $8M | $0.25 | $2.8M |
Full financial statements: income, balance sheet and cash flow
Where INBP ranks in Health care
Latest SEC filings
What Integrated Biopharma Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 25, 2026Annual report 10-K · period to June 30, 2026Revenue fell 19% to $43.9M versus the prior year; diluted EPS -$0.09 versus $0.03.
- August 20, 2026Other event 8-K
- July 2, 2026
- May 8, 2026
- May 8, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 28% to $10.1M versus the same quarter last year; diluted EPS -$0.03 versus $0.02.
- April 17, 2026Activist stake changed SCHEDULE 13D/A
- April 17, 2026Activist stake (5% or more) SCHEDULE 13D
- April 15, 2026Other event 8-K
- February 18, 2026
What is INBP worth? A DCF from its reported cash flow
Insider trades
What the people running Integrated Biopharma Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 15, 2026 | Desantis Carl10% owner | Gave as a giftindirect | 8,966,547 | - |
| April 15, 2026 | Desantis Carl10% owner | Gave as a giftindirect | 2,235,417 | - |
| April 15, 2026 | DeSantis DamonDirector, 10% owner | Gave as a giftindirect | 8,966,547 | - |
| April 15, 2026 | DeSantis DamonDirector, 10% owner | Gave as a giftindirect | 2,235,417 | - |
| April 15, 2026 | Milmoe William H.Director | Gave as a giftindirect | 8,966,547 | - |
| April 15, 2026 | Milmoe William H.Director | Gave as a gift | 2,235,417 | - |
| April 15, 2026 | Milmoe William H.Director | Gave as a giftindirect | 8,966,547 | - |
| April 15, 2026 | Milmoe William H.Director | Gave as a gift | 2,235,417 | - |
| March 24, 2026 | Desantis Carl10% owner | Gave as a giftindirect | 1,356,293 | - |
| March 24, 2026 | Desantis Carl10% owner | Gave as a giftindirect | 7,392 | - |
Who owns INBP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| DeSantis Damon13D, may seek influence with 1 related filers | 41.3% | April 17, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 15,245,809 shares in total, about $2.6M at the last price.
| Holder | Shares |
|---|---|
| DeSantis DamonDirector, 10% owner | 12,733,05812,733,058 held indirectly |
| Milmoe William H.Director | 2,512,7512,374,084 held indirectly |
Questions about INBP
What does Integrated Biopharma Inc do?
Integrated Biopharma Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker INBP.
Is Integrated Biopharma Inc profitable?
No. In fiscal 2026 it reported a net loss of $2.8M on revenue of $43.9M.
How much revenue does Integrated Biopharma Inc make?
In fiscal 2026 Integrated Biopharma Inc reported revenue of $43.9M. That is 19.3% less than a year earlier.
When did Integrated Biopharma Inc last report?
Its most recent periodic report is the annual report (10-K) filed on September 25, 2026. It covers the period to June 30, 2026.
Similar companies
Compare INBP with
Follow INBP
Get an email when Integrated Biopharma Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow INBP: get an email when it filesWhere the numbers come from
Financial figures are the values Integrated Biopharma Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.